# US 2012/0252690 A1 · Method for detecting balanced chromosomal aberrations in a genome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252690 A1
- Document ID: US20120252690A1
- Status: Published application
- Kind: A1
- Application number: 13/458,608
- Filed: 2012-04-27
- Published: 2012-10-04
- Earliest claimed: 2009-10-30
- Assignees: Roche Diagnostics Operations, Inc.
- Inventors: Martin Dugas; Vera Grossmann; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; Hans-Ulrich Klein; Alexander Kohlmann; Susanne Schnittger
- Web page: https://patentgrep.com/patent/US20120252690A1

## CPC

- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/6837: using probe arrays or probe chips (C12Q1/6874 takes precedence)
- C12Q 1/6855: Ligating adaptors
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The present disclosure provides methods and systems for the capture and enrichment of target nucleic acids and analysis of the enriched target nucleic acids for detecting balanced chromosomal aberrations including translocations and inversions. The present disclosure provides for the enrichment of targeted sequences in a format whereby one fusion partner gene on a capturing platform is represented to allow subsequent sequencing of chimeric nucleic acids (i.e., nucleic acid strands that carry information on different DNA regions of a genome). Such a design enables identification of novel fusion partner genes occurring as a result of a chromosomal translocation or inversion.

## Claims

### Claim 1

A method for detecting balanced chromosomal aberrations in a genome of an organism, the method comprising the steps of:
(a) exposing fragmented, denatured nucleic acid molecules of the genome to a plurality of oligonucleotide probes bound to different positions of a solid support, the nucleic acid molecules having an average size of about 100 to about 1000 nucleotide residues and the oligonucleotide probes having an average size of about 20 to about 100 nucleotide residues;
(b) separating nucleic acid molecules bound to one or more of the oligonucleotide probes from nucleic acid molecules not bound to one or more of the oligonucleotide probes;
(c) eluting the nucleic acid molecules bound to one or more of the oligonucleotide probes from the solid support;
(d) sequencing the nucleic acid molecules eluted in said step of eluting, whereby a determined sequence for the nucleic acid molecules is obtained;
(e) comparing the determined sequence to a database comprising a reference genome sequence;
(f) identifying sequences in the determined sequence which only partially match or do not match with sequences of the reference genome; and
(g) detecting at least one balanced chromosomal aberration.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the oligonucleotide probes comprise a linker for binding to the solid support.

### Claim 3 (depends on 1)

The method according to claim 1, further comprising the step of ligating at least one adaptor molecule to at least one end of the nucleic acid molecules prior to step (a).

### Claim 4 (depends on 3)

The method according to claim 3, further comprising the step of amplifying the nucleic acid molecules which bound to one or more of the oligonucleotide probes with at least one primer comprising a sequence which specifically hybridizes to the adaptor molecule, said step of amplifying being carried out after step (c).

### Claim 5 (depends on 4)

The method according to claim 4, wherein the at least one primer and the at least one adaptor sequence are removed in silico prior to step (d)

### Claim 6 (depends on 1)

The method according to claim 1, further comprising the step of purifying the nucleic acid molecules which bound to one or more of the oligonucleotide probes prior to step (d).

### Claim 7 (depends on 6)

The method according to claim 6, further comprising the step of amplifying the purified nucleic acid molecule prior to step (d) by emulsion polymerase chain reaction.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the nucleic acid molecules are genomic DNA molecules containing at least one chromosome of an organism with a size of at least about 50 kb.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the oligonucleotide probes contain at least one of an exon sequence, an intron sequence, and a regulatory sequence from the at least one chromosome of the organism.

### Claim 10 (depends on 7)

The method according to claim 7, wherein probes with highly repetitive sequences are excluded.

### Claim 11 (depends on 7)

The method according to claim 7, wherein the database comprising the reference genome contains at least 95% of the at least one chromosome of the organism.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the solid support comprises one of a nucleic acid microarray and a population of beads.

### Claim 13

A method for detecting balanced chromosomal aberrations in a genome, the method comprising the steps of:
(a) providing a solid support comprising a plurality of different oligonucleotide probes bound to different positions of the solid support, the oligonucleotide probes having an average size of about 20 to about 100 nucleotides;
(b) providing a plurality of fragmented and denatured nucleic acid molecules having an average size of about 100 to about 1000 nucleotide residues;
(c) amplifying the oligonucleotide probes, whereby a plurality of amplification products are generated, the plurality of amplification products including a binding moiety, the amplification products being maintained in solution;
(d) hybridizing the target nucleic acid molecules to the amplification products in solution under specific hybridizing conditions, whereby a plurality of hybridization complexes are generated;
(e) separating the hybridization complexes from nucleic acid molecules not hybridized to the amplification products;
(f) separating the hybridized target nucleic acid molecules from the amplification product comprising the hybridization complex,
(g) sequencing the target nucleic acid molecules separated in said step of separating, whereby a determined sequence for the nucleic acid molecules is obtained;
(h) comparing the determined sequence to a database comprising a reference genome;
(i) identifying sequences in the determined sequence which only partially match or do not match with sequences of the reference genome,
(i) detecting at least one balanced chromosomal aberration.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the oligonucleotide probes comprise a linker for binding to the solid support.

### Claim 15 (depends on 13)

The method according to claim 13, wherein the oligonucleotide probes comprise a primer binding sequence at least one end.

### Claim 16 (depends on 13)

The method according to claim 13, wherein the binding moiety is a biotin binding moiety.

### Claim 17 (depends on 13)

The method according to claim 13, wherein said step of separating comprises binding said biotin binding moiety to a streptavidin coated substrate.

### Claim 18 (depends on 13)

The method according to claim 13, wherein the nucleic acid molecules are genomic DNA molecules containing at least one chromosome of an organism with a size of at least about 50 kb.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the oligonucleotide probes contain at least one of an exon sequence, an intron sequence, and a regulatory sequence from the at least one chromosome of the organism.

### Claim 20 (depends on 19)

The method according to claim 19, wherein probes with highly repetitive sequences are excluded.
